Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer

M Noguchi, H Kikuchi, M Ishibashi, S Noda, M Noguchi, H Kikuchi, M Ishibashi, S Noda

Abstract

We addressed in this study whether quantifying the extent of disease on bone scans can predict the disease death of patients with advanced prostate cancer using computer-assisted image analysis. Pretreatment radionuclide bone scans were reviewed in 56 patients with bone metastases from prostate cancer, and the percentage of the positive area on a bone scan (%PABS) was quantified automatically using a personal computer with the NIH Image program for estimation of the accurate extent of metastatic bone lesions on a bone scan. The significance of the %PABS as well as the other known prognostic factors was evaluated using univariate and multivariate Cox proportional hazards analysis. In univariate regression analysis, the %PABS (P=0.0155), serum alkaline phosphatase (P=0.0272), the tumour grade based on biopsy (P=0.044) and the number of bone lesions on bone scans (P=0.0388) were well associated with disease-specific survival. In multivariate analysis, the %PABS (P=0.0155, relative risk ratio 2.603), but not the other factors, was the independent predictor of the disease death. These results suggest that the %PABS is a novel parameter for predicting the prognosis of patients with advanced prostatic cancer.

Figures

Figure 1
Figure 1
%PABS measurement. The %PABS is calculated using the formula %PABS=(positive area on bone scan/square area)×100. (A) The estimated square area is multiplied by the width at the gluteal region to the height of the entire skeleton on the bone scan. (B) Direct tracings of same hot spot perimeters in B from the bone scan. (C) Computer tracings after measurement by NIH Image.
Figure 2
Figure 2
Correlation between the %PABS and the number of bone lesions.
Figure 3
Figure 3
Correlation between the %PABS and the EOD grade from 1 to 4.
Figure 4
Figure 4
A serial bone scan in a patient who showed improvement of bone metastasis after hormonal therapy: (A) pretreatment; (B) 12 months after treatment; (C) 27 months after treatment.
Figure 5
Figure 5
Kaplan–Meier plot shows disease-specific survival after treatment of metastatic prostate cancer for those with less than 4.6 %PABS and greater than 4.6 %PABS (P=0.011).

References

    1. Amico S, Liehn JC, Desoize B, Larbre H, Deltour G, Valeyre J (1991) Comparison of phosphate isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. Clin Nucl Med 16: 643–648
    1. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA (1991) Independent prognostic factors in patients with metastatic (stage D2) prostate cancer: The zoladex study group. JAMA 265: 618–621
    1. Chybowski FM, Keller JL, Bergstralh EJ, Oesterling JE (1991) Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145: 313–318
    1. Citrin DL, Cohen AI, Harberg J, Schlise S, Hougen C, Benson R (1981) Systemic treatment of advanced prostatic cancer: development of a new system for defining response. J Urol 125: 224–227
    1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr DG, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419–424
    1. Dann J, Castronovo Jr FP, McKusick KA, Griffin PP, Strauss HW, Pout Jr GR (1987) Total bone uptake in management of metastatic carcinoma of the prostate. J Urol 137: 444–448
    1. Emrich LJ, Priore RL, Murphy GP, Brady MF, and the investigators of the national prostatic cancer project (1985) Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45: 5173–5179
    1. Erdi YU, Humm JL, Imbrico M, Yeung H, Larson M (1997) Quantitative bone metastases analysis based on image segmentation. J Nucl Med 38: 1401–1406
    1. Ernst DS, Hanson J, Venner PM (1991) Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol 146: 372–376
    1. Gleason DF (1977) Histologic grading and clinical staging of carcinoma of the prostate. In Urologic Pathology, The Prostate. Tannenbaum M (ed) pp 171–197. Philadelphia, PA: Lea & Febiger
    1. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher I (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 4: 1765–1772
    1. Noguchi M, Noda S (2001) Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166: 1106–1110
    1. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrik MV, Elton RA (1993) Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Brit J Urol 72: 933–936
    1. Risteli J, Elomana I, Niemi S, Novamo A, Risteli L (1993) Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39: 635–640
    1. Scabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher H (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17: 948–957
    1. Schaffer DL, Pendergrass HP (1976) Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 121: 431–434
    1. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial scan. Cancer 61: 195–202

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다